Kingdon Capital Management, L.L.C. Revance Therapeutics, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $639 Million
- Q2 2025
A detailed history of Kingdon Capital Management, L.L.C. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 100,000 shares of RVNC stock, worth $256,999. This represents 0.23% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$256,999% of portfolio
0.23%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
20Shares Held
10.1MCall Options Held
360KPut Options Held
0-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL423KShares$1.09 Million0.0% of portfolio
-
Rothschild & CO Asset Management Us Inc. New York, NY370KShares$949,9950.1% of portfolio
-
International Biotechnology Trust PLC London, X0289KShares$742,0251.12% of portfolio
-
Credit Suisse Ag Zurich, V8180KShares$462,9800.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...